Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
Public ClinicalTrials.gov record NCT07211178. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
For patients with breast cancer, it's important to find any remaining cancer cells after they've had their main treatment. Even a few cells, called minimal residual disease (MRD), can lead to the cancer coming back later. A way to find these cells is by looking for tiny bits of cancer DNA that are shed into the blood. This is called circulating tumor DNA (ctDNA). A simple blood test, often called a liquid biopsy, can detect this ctDNA. This research aims to see if finding this cancer DNA in the blood can help predict if a patient's cancer will return. It also may help find out if the treatment is working. Ultimately, the results of this research may help doctors better manage breast cancer and develop new and improved tests and treatments.
Study identification
- NCT ID
- NCT07211178
- Recruitment status
- Recruiting
- Study type
- Observational
- Phase
- Not listed
- Enrollment
- 900 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years to 99 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 26, 2025
- Primary completion
- Nov 30, 2032
- Completion
- Nov 30, 2033
- Last update posted
- Jun 11, 2026
2025 – 2033
United States locations
- U.S. sites
- 14
- U.S. states
- 13
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Birmingham Hematology Associates | Birmingham | Alabama | 35223 | Recruiting |
| PIH Health Whittier Hospital | Whittier | California | 90602 | Recruiting |
| Cleveland Clinic Florida | Weston | Florida | 33331 | Recruiting |
| Southern Illinois Hospital Services | Carbondale | Illinois | 62902 | Recruiting |
| Cancer Care Specialist of Illinois | O'Fallon | Illinois | 62269 | Recruiting |
| Goshen Center for Cancer Care | Goshen | Indiana | 46526 | Recruiting |
| Trinity Health | Ann Arbor | Michigan | 48106 | Recruiting |
| Oncology Hematology Associates | Springfield | Missouri | 65807 | Recruiting |
| Cancer Care Specialist of Reno | Reno | Nevada | 89511 | Recruiting |
| Summit Medical Group | Florham Park | New Jersey | 07932 | Recruiting |
| University of Cincinnati Medical Center | Cincinnati | Ohio | 45219 | Recruiting |
| Nashville General | Nashville | Tennessee | 37208 | Recruiting |
| Cancer Care Northwest | Spokane Valley | Washington | 99216 | Recruiting |
| Gunderson Health | La Crosse | Wisconsin | 54601 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07211178, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 11, 2026 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07211178 live on ClinicalTrials.gov.